About Sub-Q Ig Therapy

Your patients with primary immune deficiency disease (PIDD) may wish to join the thousands of Vivaglobin® patients and families who have found scheduling freedom and flexibility while their physicians manage their care.

As with any new experience, your healthcare team or your patients may have questions about moving to Vivaglobin® Sub-Q for PIDD.

Within this Web site, you’ll find information that can help you:

  • Learn more about Sub-Q
  • Identify patients who are good candidates for Sub-Q
  • Compare and contrast the advantages of Sub-Q and IV PIDD therapies

You may also register to join the growing number of physicians who believe in the safety and efficacy of Vivaglobin® self-administration for PIDD, and in the achievement of steady-state serum Ig levels—further enhancing their patients’ lives.

Learn about Hizentra™ (Immune Globulin Subcutaneous [Human] 20% liquid), a new Sub-Q Ig.

Next: Sub-Q vs. IV Therapy


CSL Behring

Important Safety Information  |   Prescribing Information  |   Contact Us  |   Site Map
Privacy Statement  |   Terms of Use  |   About CSL Behring

© CSL Behring 2010. The product information on this site is intended for US residents only.